Ultrafiltration Versus Medical Therapies in the Management of the Cardio Renal Syndrome

Cardio-renal Syndrome Clinical Trial

— UF-CARE  

Official title:

Ultrafiltration Versus Medical Therapies in the Management of the Cardio Renal Syndrome

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02846337
• Other study ID #: 69HCL15_0077
• Secondary ID: 2016-A00518-43
• Status: Recruiting
• Phase: N/A
• Start date: March 31, 2017
• Est. completion date: September 30, 2021

Study information

• Verified date: October 2018
• Source: Hospices Civils de Lyon
• Contact: Laurent JUILLARD, Pr
• Phone: (0)472 110 159
• Email: laurent.juillard[@]chu-lyon.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Type 2 cardio renal syndrome is defined by the occurrence or the exacerbation of a kidney failure induced by a chronic heart failure. Sodium overload is one of the main causes leading to the occurrence or the exacerbation of this syndrome. Some patients have a massive sodium retention on which medications are not effective enough. These patients have no further therapeutic options because of the refractory congestion and a 3-months mortality rate around 15%, frequent rehospitalization (3-months rehospitalization rate at 71%) and an excessively impaired quality of life.

For those refractory heart failure with cardio renal syndrome, nephrology departments resort to non-medication sodium extraction (hemodialysis, peritoneal dialysis, isolated ultrafiltration). Between 2002 and 2008, 927 French patients would have start dialysis in this situation. In 2013, 174 patients start dialysis in 97 dialysis centers. French National Authority of Health recently published new Good Practice Guidance thereupon, strengthened by the increasing number of publications and the widespread use of this technique. There is therefore a consensus among professionals about the benefits of such a technique in those indications. However, bibliographical data are not strong enough to support a strong level of evidence. None of foresight strategies have been compared to others in a proper randomized controlled trial, and there is no clue about any suspected superiority from one strategy to another.

So far, the investigators propound invasive, expensive and not validated techniques to patients with functional and vital prognosis altered. The investigators think it's essential to prove the efficacy of such an approach. They wish to quantify those techniques impact on rehospitalization, with a consideration for the potential survival impact.

It seems unethical to evaluate separated techniques, taking in account that patients with severe heart failure will switch from one technique to another among their care. It is therefore crucial to validate benefits from an invasive procedure (hemodialysis, peritoneal dialysis, isolated ultrafiltration) compared to a medication-restricted care.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 154
• Est. completion date: September 30, 2021
• Est. primary completion date: September 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Severe heart failure with recurring congestive symptoms and at least one the following criteria :

• At least 2 hospitalization > 24 hours for congestive symptoms among the 12 months before the inclusion, whose latest one was in the 6 months before the inclusion

• Persistent congestive symptoms throughout 30 days (case history) before the randomization: dyspnea NYHA III or IV, lower limbs edema and/or ascites.

• Diuretic treatment with at least 250mg furosemide per day (or 6mg bumetanide)during at least 1 month

• Cardiac medical treatment enhanced by the European cardiology society guidance (except intolerance, and/or contraindication) and according to patient cardiologist.

• Non terminal kidney disease or failure : estimated glomerular filtration rate (GFR) (CKD-Epi formula) between 20 and 90 mL/min/1.73m² (or GFR estimated between 60 and 90 mL/min/1.73m² with proteinuria and/or hematuria) and urea rate under 50mmol/L

Exclusion Criteria:

• Cardiogenic shock or situations that contraindicate the ultrafiltration technique elsewhere than shock room

• Patient who already had long course ultrafiltration for more than 3 months, or not available because of end-stage renal failure

• Biventricular pacemaker implementation, single or dual chamber pacemaker implementation, or defibrillator implementation up to 15 days before the inclusion

• Vasoactive drugs ambulatory treatment (dobutamine, dopamine, adrenalin, noradrenalin)

• General condition incompatible with any ultrafiltration techniques

• Age under 18

• Pregnant or lactating women

• Law-protected patients

• Patients that can't submit to the follow-up for geographical, social or mental reasons

• Unwillingness to be treated by ultrafiltration techniques

• Patients who don't belong to the national social security system, or similar system.

Related Conditions & MeSH terms

• Cardio-renal Syndrome
• Syndrome

Intervention

Procedure:
• ULTRAFILTRATION
Peritoneal dialysis: at least one daily contact, 5 days a week minimum, with a hypertonic solution. Le number of contact et the stasis duration will be decided by the practitioner. Hemodialysis: at least one hemodialysis per week, one hemofiltration and/or hemodiafiltration per week, and at least 2 liter of ultrafiltrate extraction per week. In case of serious interdialytic weight gain, and/or hemodynamic unsteadiness, sessions can be up to 6 per weeks. Sessions duration will be adjusted to the needful ultrafiltrate and hemodynamic tolerance. Isolated ultrafiltration: at least once a week, and includes an extraction of minimum 2 liter ultrafiltrate in less than 4 hours. It could be done, according to routines and department capacity, on a hemodialysis generator, plasmatic exchange generator, or mobile ultrafiltration device.
• ENHANCED MEDICAL TREATMENT
Close cardiologic and nephrologic follow-up, minimum 4 times a year, This incidence matches the heart failure, and chronic kidney failure care guidance for our sample Medical care adjustment in order to apply European and American guidance for chronic heart failure care Hydric, caloric, peptic and sodium input evaluation by a dietician, and adjustment if needed Physical rehabilitation suggestions by a physiologist Evaluation of an interventional approach requirement, and implementation if needed (pacemaker, defibrillator, cardiac resynchronization, diagnosis and therapeutic coronary angiography, ventricular stimulator) according to European and American guidance.

Locations

Country	Name	City	State
France	Hospices Civils de Lyon, Hôpital E Herriot, Service de néphrologie, 5 place d'Arsonval	Lyon	Rhones Alpes

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	death and/or unscheduled hospitalization	The primary outcome measure is a combined measure including death whatever the cause, and/or unscheduled hospitalization for acute decompensated heart failure. For each groups, deaths, cause and time of deaths will be recorded. Hospitalization date, duration, location, and reason will be recorded. The "hospitalization" setting and the "acute decompensated heart failure" setting will be endorsed by an event validation committee.	up to 12 months post-randomization
Secondary	Survival	number of days spent alive and not hospitalized	12 months
Secondary	Survival	Intervention effect on one-year overall survival	12 months
Secondary	Hospitalization for acute decompensated heart failure	Intervention effect on : Period before first unscheduled hospitalization for acute decompensated heart failure; Number and duration of hospitalizations for acute heart failure (scheduled or not) throughout the year; Number and duration of unscheduled hospitalization for acute heart failure throughout the year.	up to 12 months post- randomization
Secondary	Change in NYHA classification	New York Health Association - Measurement scale to classify heart failure in 4 stages (stage 1 ; no symptoms)	randomization day and 12 months post randomization.
Secondary	Change in 6MWT - Six-Minute Walk Test	Six-minute walk test with an experimented physiologist. The distance in meters is retained.	randomization day and 12 months post randomization.
Secondary	Change in MLwHF form	Minnesota Living with Heart Failure - Quality of life self-administered survey focusing on heart failure symptoms (21 items with 1 : slightly to 5 : al lot) Safety issue? 0 Yes 1 No	randomization day and 12 months post randomization.
Secondary	Change in SF36 form	Short Form 36 : Quality of life self-administered survey with 36 items about 8 dimensions including a physical and mental score.	randomization day and 12 months post randomization.
Secondary	Death occurrence attributable to ultrafiltration technique	Safety: Death occurrence attributable to ultrafiltration technique, validated by an independent supervisory board, and any adverse event.	up to 12 months post- randomization
Secondary	Change in Brain Natriuretic Peptide and/or NT-Probating Natriuretic Peptide rate	Following biological features variation : Brain Natriuretic Peptide (BNP) and/or NT-ProBNP	randomization day and 12 months post randomization
Secondary	Change in total bilirubin rate	Following biological features variation : total bilirubin	randomization day, then 3, 6 and 12 months post randomization
Secondary	Change high-sensitivity T troponin rate	Following biological features variation : high-sensitivity T troponin	randomization day and 12 months post randomization
Secondary	Change in hemoglobin rate	Following biological features variation : hemoglobin	randomization day and 12 months post randomization
Secondary	Change in Left ventricular ejection fraction (LVEF)	Following echocardiographic parameters features : left systolic function (LVEF)	randomization day and 12 months post randomization
Secondary	Change in Tricuspid annular plane systolic excursion (TAPSE)	Following echocardiographic parameters features :right systolic function (TAPSE)	randomization day and 12 months post randomization
Secondary	Change in tricuspid annular velocity	Following echocardiographic parameters features : right systolic function assessed by tricuspid annular velocity measured with Pulsed Doppler tissue imaging	randomization day and 12 months post randomization
Secondary	Change in transmitral patterns classification	Following echocardiographic parameters features : left diastolic function assessed by transmitral patterns classification	randomization day and 12 months post randomization
Secondary	Change in E/E' ratio	Following echocardiographic parameters features : E/E'	randomization day and 12 months post randomization
Secondary	Change in pulmonary artery systolic pressure (PASP)	Following echocardiographic parameters features : pulmonary artery systolic pressure (PASP)	randomization day and 12 months post randomization
Secondary	Change in Surface of the Left Atrium	Following echocardiographic parameters features : Surface of the Left Atrium	randomization day and 12 months post randomization
Secondary	Change in right atrial pressure	Following echocardiographic parameters features : Impact on right ventricular function assessed by right atrial pressure	randomization day and 12 months post randomization
Secondary	Change in cardiac index	Following echocardiographic parameters features : cardiac index	randomization day and 12 months post randomization
Secondary	Change in cardiac flow	Following echocardiographic parameters features : cardiac flow	randomization day and 12 months post randomization